Biocare Medical, a San Francisco, CA-based provider of immunohistochemistry (IHC) and FISH, acquired Empire Genomics, a Buffalo, NY-based provider of molecular biomarkers.
The amount of the deal was undisclosed.
Together, Biocare Medical and Empire Genomics will bring an expanded offering of solutions to those researching and diagnosing cancer around the world.
Empire Genomics is a provider of FISH and ISH, offering over one million biomarkers. These biomarkers enable research and clinical institutions to bring clinically relevant tests. The company enables research to transform into impactful clinical and research tools worldwide. The comprehensive product portfolio includes Fluorescence in situ Hybridization (FISH) and Chromogenic in situ Hybridization (CISH) probes designed and optimized for specific diseases, genes, or regions across the entire human and mouse genomes.
Led by CEO Luis de Luzuriaga, Biocare Medical is a provider of solutions for cancer research and diagnostics, providing: reagents, including tissue-conserving simultaneous Multiplex IHC antibody cocktails and detections; Customer Care; and a comprehensive suite of instrumentation for IHC, molecular, and histology testing. Its reagent portfolio includes primary antibodies, Multiplex IHC, and FISH probes for target indications. Biocare also offers a line of polymer detections for clinical, human, and animal research that deliver high sensitivity and exceptionally low background. The company’s automated instrument platforms, intelliPATH and ONCORE Pro, have been designed to meet every need from high throughput clinical diagnostics to flexible research requirements.
Customers include clinical anatomic pathology laboratories, pharmaceutical companies, CROs, and biotechnology companies as well as academic, government, military, and other non-profit laboratories
